Entity
  • Smart Immune

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    5,774
  • Activities

  • Technologies

  • Entity types

  • Location

    Faculté de Médecine - Site Cochin, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France

    Paris

    France

  • Employees

    Scale: 11-50

    Estimated: 36

  • Engaged corporates

    24
    12 14
  • Added in Motherbase

    1 year, 8 months ago
Description
  • Value proposition

    Pioneering thymus-empowered T-cell platform to fight cancer and infection


    Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.

    Biotechnology, Cell therapy, CAR T, Immuno-oncology, NK cells, T cells, Immune reconstitution, T cell progenitors, Lymphoid progenitors, Naive cells, HSC differentiation, and Thymic selection

  • Original language

    Pioneering thymus-empowered T-cell platform to fight cancer and infection


    Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.

  • Unlocking the power of allogeneic T-cell therapies to fight cancer and infection

    Smart Immune is a clinical-stage biotechnology company developing ProTcell a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system against cancers and infections.

  • https://www.smart-immune.com/
Corporate interactions BETA
Corporate TypeTweets Articles
numeum
numeum
IT Services and IT Consulting
numeum
IT Services and IT Consulting
Other

27 Mar 2023


La French Tech
La French Tech
Media, Government Administration
La French Tech
Media, Government Administration
Other

20 Dec 2023


Paris Biotech Santé
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Other

2 Dec 2023


RIVP
RIVP
Real Estate, Social Housing
RIVP
Real Estate, Social Housing
Other

24 Jan 2023


Similar entities
Loading...
Loading...
Social network dynamics